PRPO Profile
Precipio, Inc., a specialized healthcare solutions provider, delivers advanced diagnostic products, reagents, and services primarily in the United States. The company is at the forefront of blood cancer diagnostics, offering a range of services and proprietary technologies designed to enhance the accuracy and efficiency of cancer detection and treatment. Precipio’s flagship offerings include IV-Cell, a proprietary cell culture media that supports the simultaneous culturing of four hematopoietic cell lineages, facilitating comprehensive cancer research and diagnostic processes.
The company’s HemeScreen product is a suite of robust genetic diagnostic panels that provide critical insights into hematologic malignancies, enabling precise and actionable results for clinicians. Precipio also markets ICE-COLD PCR, a patented specimen technology that significantly boosts the sensitivity of molecular-based tests, improving the detection of low-abundance mutations and genetic abnormalities in patient samples. In response to the COVID-19 pandemic, Precipio has developed and offered antibody tests to aid in the detection and monitoring of the virus.
In addition to its diagnostic products, Precipio sells ICE-COLD PCR technology kits to bio-pharma customers, supporting their research and development efforts. The company maintains strategic collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. These partnerships enhance Precipio’s ability to drive innovation and integrate cutting-edge technologies into its product offerings.
Founded in New Haven, Connecticut, Precipio, Inc. has established itself as a leader in the field of diagnostic solutions for cancer and other critical diseases. Its commitment to advancing diagnostic accuracy through proprietary technologies and strategic collaborations underscores its role in improving patient outcomes and supporting the broader healthcare community. The company’s continued focus on innovation and excellence reflects its dedication to addressing complex medical challenges through advanced diagnostic solutions.
|
